Led · Seed · Nov 2023

Frieda Health is a Berlin-based femtech startup developing a digital health platform to support women during menopause, particularly those aged 45 and above. The platform integrates medical and psychological expertise with digital technology to provide comprehensive support across biological, emotional, and psychological aspects. The team includes professionals in health data, software development, gynecology, and psychology. With new funding, Frieda plans to expand research and development, refine its digital platform, and grow its user base. CEO Valentina Ullrich says the company aims to address the treatment gap in menopause and rethink 'positive or healthy aging' within preventive health. Frieda secured EUR 2.5 million in pre-seed funding from Maximon Longevity Co-Investment Fund to support ongoing development.

Led · Equity · May 2023

Biolytica has developed Biolytica NEXUS, an AI-driven health data platform that aggregates, visualizes and analyzes genomics, blood and epigenetic biomarkers, microbiome data, wearable-device and lifestyle information. The platform is sold to healthcare professionals—preventive medicine institutions, longevity centres, personalised wellness clinics—and insurance companies, while Biolytica also offers B2C concierge health optimization and longevity programs delivered by its team of longevity experts. Biolytica NEXUS traces conceptual origins to 2016, was in stealth from October 2021, and made its initial launch this year, already reporting promising metrics and results. The company uses AI to generate personalized health journeys, improve predictions, and support preventive, human-focused care aimed at extending healthspan. With the recent €5.34 million financing from Maximon Longevity Co-Investment Fund, Biolytica plans to expand R&D, scale services to a wider client base and collaborate with leading experts and clinics. The startup is positioning itself in the growing longevity and preventive-health market to become a leading data platform for personalized health and prevention.

Led · Seed · Jun 2022

Avea is a Swiss startup focused on science-based longevity supplements intended to extend human healthspan. The company has enlisted scientists and researchers in the field of longevity to build a supplement line meant to optimize long-term health and to slow or reverse some signs of aging. Avea launched its first products in February 2022; its initial formulation is described as a synergistic blend reflecting the latest ageing and healthspan research. The startup raised €2.43 million in funding to support growth. It plans to use the proceeds to expand across Switzerland, Germany, Austria and the U.K. Co-founder Sophie Chabloz framed a longevity supplement regimen as essential alongside diet, exercise and sleep, and Maximon's Tobias Reichmuth noted the global longevity market opportunity.